BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

...company work. The Perceptive Xontogeny Venture (PXV) fund led the company’s series A round, with Drive Capital...
...of employees: Undisclosed Funds raised: At least $40 million Investors: Perceptive Xontogeny Venture (PXV) fund, Drive Capital...
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
Items per page:
1 - 2 of 2
BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

...company work. The Perceptive Xontogeny Venture (PXV) fund led the company’s series A round, with Drive Capital...
...of employees: Undisclosed Funds raised: At least $40 million Investors: Perceptive Xontogeny Venture (PXV) fund, Drive Capital...
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
Items per page:
1 - 2 of 2